Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
Mitchga (Nemolizumab) is the first antibody drug targeting IL-31 receptor A, for the treatment of itching associated with atopic dermatitis (only when existing treatment is insufficiently effective).
Lead Product(s): Nemolizumab
Therapeutic Area: Dermatology Product Name: Mitchga
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
Moizerto (Difamilast) Ointment is a non-steroidal, topical phosphodiesterase type-4 inhibitor (commonly called a PDE4 inhibitor), improve the symptoms of atopic dermatitis.
Lead Product(s): Difamilast
Therapeutic Area: Dermatology Product Name: Moizerto
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
The approval of Mitchga, the first antibody-drug targeting interleukin-31, is based on the results from a Japanese phase III clinical study in patients with moderate to severe AD who are older than 13 years old and are tolerant to existing treatments.
Lead Product(s): Nemolizumab
Therapeutic Area: Dermatology Product Name: Mitchga
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
Moizerto Ointment (difamilast), in 1% and 0.3% formulations, is a non-steroidal topical phosphodiesterase type 4 inhibitor (PDE4 inhibitor). Moizerto Ointment was discovered by Otsuka in Tokushima Research Institute and is the first topical PDE4 inhibitor approved in Japan.
Lead Product(s): Difamilast
Therapeutic Area: Dermatology Product Name: Moizerto
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2021
Details:
Approval is based on the data from a Japanese phase III clinical trial. The proportion of patients achieving at 100 of the target pyoderma gangrenosum ulcer area reduction at Week 26 of Humira administration was 54.5% in the trail.
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Humira
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2020
Details:
Sofpironium bromide gel was deemed to be safe and well tolerated in this study, as well as in the accompanying 52-week long-term safety extension study in Japan. Japan is the first country to approve sofpironium bromide with commercial launch expected later this year.
Lead Product(s): Sofpironium Bromide
Therapeutic Area: Dermatology Product Name: Ecclock
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Fresh Tracks Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2020
